ATHM vs META

The deterministic scorecard reveals a mixed financial health with a Piotroski F-Score of 6/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a full distress risk assessment. Despite attractive valuation metrics such as a low P/E of 13.07 and a Price/Book of 0.79, the company faces significant headwinds including negative earnings momentum, declining revenue growth, and a dangerously high payout ratio exceeding 100%. The stock trades below analyst target of $27.71 yet remains in a prolonged downtrend with a 5Y return of -75.8%, signaling deep market skepticism. Strong gross margins and zero debt are offset by deteriorating profitability trends and weak technical posture.

META exhibits exceptional fundamental health with a Piotroski F-Score of 8/9, indicating strong financial strength across profitability, leverage, and operating efficiency. While the current price of $612.42 trades at a premium to the Graham Number ($213.17) and the growth-based Intrinsic Value ($542.14), the PEG ratio of 0.94 suggests the stock is undervalued relative to its high growth rate. Strong revenue growth (23.8%) and a low forward P/E (17.03) outweigh the bearish technical trend and insider selling. The company's dominant market position and consistent earnings beats support a bullish long-term outlook.